fda compounding semaglutide enforcement november 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots FDA Warns on Certain Forms

Conditions such as heart disease, chronic kidney disease, and obstructive sleep apnea may affect which GLP-1 medication is chosen for treatment

Months 6 to 12: The SURMOUNT-5 trial published in the NEJM in 2025 found tirzepatide produced 20.2% body weight loss compared to 13.7% for semaglutide over 72 weeks in patients with obesity

The head-to-head comparison between semaglutide and tirzepatide remains the most frequently consulted resource for patients weighing their options

Whether you are evaluating your current vendor or searching for a new source entirely, the information here will help you make a decision grounded in data rather than marketing claims

TrimRX is not a dietary supplement

The purpose is to confirm the Phase 2 results at scale, identify rare side effects, and establish long-term safety data